Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

Home  >>  Allgemein  >>  Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

On Oktober 12, 2017, Posted by , In Allgemein, With Kommentare deaktiviert für Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

Train – Pitch- Meet – Training and Selection of Europe’s best Biotech Startups

Catapult

International Biotech Semifinal of the European Health Catapult

Heidelberg, 12 October 2017

On October 4-6, BioRN, together with EIT Health, organized the Biotech Semifinal of the European Health Catapult. The Biotech semifinal consisted of two training days on October 4/5 at the Hotel Villa Toscana in Leimen|Heidelberg and one competition day on October 6 at the Studio Villa Bosch in Heidelberg.

13 innovative start-up teams from all over Europe (9 countries) were participating: Affichem, Elthera AG, EVEXyS, LifeTag, Lumobiotics, Microbrain Biotech, Nanoligent, NoMicro, Peptomyc, SpyBiotech, SUN Bioscience, Prelife, Vitroscan.

The aim of the training days was to mentor and prepare the start-up teams in the topics of e.g. Drug Development and Regulatory Affairs, Business Plan Development, Financing, Marketing and Market Access, Negotiation and Intellectual Property (IP). 9 Experienced coaches and mentors/experts of different expertise coming from the healthcare industry or investment sector were passionate to advise the startups in intense one on one sessions during the two training days. The spirit during the semifinal was very supportive. The vivid exchange with peers and mentors generated an atmosphere of entrepreneurial spirit and support.

In addition, the start-ups were intensively prepared for their 5-min pitch presentation in front of the jury on October 6th. A professional pitch trainer was working intensively with the entrepreneurs on their presentation skills and pitch decks.

During the competition day on October 6 at the Studio Villa Bosch in Heidelberg, the 13 start-ups presented their innovative technologies and businesses in enthusiastic 5-minute live pitches. Renowned jury members with healthcare and biotech technology backgrounds, selected the 7 best Biotech start-ups in the European Health Catapult competition that will enter the next stage, the final during the EIT Health Summit in London on 4-5 December.

Around 60 participants including healthcare professionals and investors from the Venture Capital, Crowdinvestment, Business Angels and Family Office were participating in the event. In one on one meetings interested investors, leading healthcare professionals could meet up with the startups to discuss potential collaboration, investment or partnerships.

The selected 7 Finalists are (alphabetical order):

  • Affichem: Development of Dendrogenins for the prevention/treatment of deafness.
  • Elthera AG: Development of an antibody against the cancer treatment target L1CAM
  • LifeTag: Diagnostic solutions to detect chronic metabolic diseases.
  • Lumobiotics: Photoswitchable anticancer & antimicrobial peptide drugs.
  • Peptomyc: Myc inhibitor protein with cell penetrating properties for cancer treatment
  • SpyBiotech: Bacterial superglue technology to generate vaccines more quickly
  • SUN Bioscience: organoid culture platform for personalized treatment (cystic fibrosis)

The 7 finalists have now the chance to win prizes of: First prize 20.000 Euro, Second prize 15.000 Euro and third prize 10.000 Euro in the Biotech Category.

BioRN_Halfinale_4854

The participating 13 start-up teams

But the other semifinalists that haven’t won a ticket for the final in London are not leaving with empty hands. As a partner of the EIT Health Accelerator, Amazon Web Services provides all winners of regional EHC selection events (= EHC semi-finalists) with $100,000 in AWS Promotional Credit for 1 year (or $10,000 for 2 years) to get and test the right infrastructure needed for scaling and growing any size business. More information can be found at https://aws.amazon.com/activate at [Portfolio Plus]“. In addition, the alumni network of EIT Health will support all semi-finalists on their development path to success.

Another highlight of the event on October 6 was the keynote given by Sierk Poetting, the CFO of BioNTech, who was providing an overview of the Company´s strategy and its recent big successes. His advice to the young entrepreneurs was to believe in and be motivated by their science and technology, the rest will come along.

The European Health Catapult competition will run again in the next year and we are looking forward to meeting the next round of innovative pioneers. Please get in touch if you are interested to apply.

BioRN_Halfinale_4840 BioRN_Halfinale_6113

              

 

 

About the European Health Catapult

The European Health Catapult is a training and competition platform for Biotech, Medtech and Digital Health startup companies that are specifically looking for Seed or Series A funding. The Accelerator includes several opportunities to stage a start-up in front of experts and international investors.

For more information visit: http://www.europeanhealthcatapult.eu/

About BioRN

Biotech Cluster Rhine-Neckar (BioRN) is one of Germany’s leading Life Science Clusters. The network counts about 200 companies, societies and research institutions, all located in a 100 km perimeter of the historical region of Heidelberg, Mannheim, Ludwigshafen, Darmstadt, Frankfurt and Karlsruhe.

The Cluster is partly based on internationally renowned research institutions such as the University of Heidelberg, the University Clinic of Heidelberg, Mannheim Technical College, the German Cancer Research Center (DKFZ), the European Molecular Biology Laboratory (EMBL) and the Max-Planck-Institute for Medical Research. Furthermore, the cluster’s profile is shaped by approximately 100 small and medium-sized companies as well as six global pharmaceutical companies. They develop, among other things, medication, diagnostic and technology platforms focusing on personalised medicine and cancer research.

For more information visit: http://biorn.org/

About EIT Health

EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the fundamentals of healthcare and thus promote suitable future conditions for healthy living, active ageing and improved wellbeing of people across Europe. EIT Health leverages the expertise of more than 135 member organisations from the pharma, diagnostics and med tech fields, payers, insurances, research institutions and universities. As one of the EIT’s Knowledge and Innovation Communities (KICs), the initiative benefits from some of the world’s best-in-class academic and research organisations and offers both higher education and business expertise. By investing in Europe’s best entrepreneurial talents and ideas, EIT Health fosters the development and commercialization of smart product and service solutions in the health sector, addressing the challenges posed by demographic change and ageing societies.

Headquartered in Munich (Germany), EIT Health has six co-location centres in London (UK/Ireland), Stockholm (Scandinavia), Barcelona (Spain), Paris (France), Mannheim and Heidelberg (Germany/Switzerland) and Rotterdam (Belgium/Netherlands), as well as regional “EIT Health InnoStars” clusters consisting of industry partners, academia, and health providers linked to seven regions in six countries – Croatia, Hungary, Poland, Portugal, Italy and Wales.

http://www.eithealth.eu/

About the Health Axis Europe

The Health Axis Europe (HAE) is a strategic alliance between the biomedical clusters Leuven (Belgium), Heidelberg (Germany), Maastricht (Netherlands) and Copenhagen (Denmark). The aim of the Health Axis Europe is to pool together the innovative energy of the three locations  For more information visit: in order to strengthen international competitiveness.

The alliance supports the initiation and coordination of large EU-promoted R&D projects, cross-border cooperation in the training and further education of talented persons, and cross-border investments and cooperation between established VC funds.

For more information visit:  www.health-axis.eu

Download press release here

Press Contact:

Dr. Birgit Rogell, Project Manager BioRN Cluster Management GmbH

Email: br@biorn.org

Phone: +49 (0) 6221 4305113

Christine Neumann, Communication & Public Affairs Manager, EIT Health Germany

Email: christine.neumann@eit-health.de

Phone: +49 (0) 621 76446114

 

Comments are closed.